Exchange: NASDAQ·Updated 07:30 PM EST
CLYM logo

CLYM Climb Bio Inc.

$9.03
$0.09
(0.97%)
Today
Closed $9.19
$0.162
(1.76%)
After Hours
Reported EarningsNov 5
Mkt Cap$539.8M
Vol770,180.00

About CLYM

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
38

Bearish Sentiment

How do you feel about CLYM?

stockpicker63
🚨 $CLYM (Climb Bio) – Swing Trade Analysis Fundamentals: 6/10 | AI Score: 7.5/10 Trend: Reversing off $8.80 support 📈 Setup: LONG (1–5 Days) Entry: $9.00 – $9.25 Target: $9.85 (TP1) | $10.15 (TP2) Stop-Loss: $8.55 Risk: High (Biotech Catalyst Rebound)
1
mastersnafu
$CLYM all my biotech stocks are getting smashed hard. Clym is recovering so this might be the beginning of another run hopefully
2
topstockalerts
Wedbush maintained Climb Bio on its list of top biotech investment ideas, reiterating an Outperform rating and a $25 price target despite recent share-price volatility and a 14% decline following clinical updates presented at the American Society of Nephrology meeting. The firm considers investor concerns about the company's clinical data overstated and sees multiple catalysts through 2027. Wedbush highlighted positive Phase 1 results for CLYM116, an experimental kidney-disease treatment, showing a 33-day half-life compared with nine days for competitor sibeprenlimab. The drug also achieved an approximately 70% reduction in Gd-IgA1 and more than 90% reductions in free APRIL, supporting a potentially differentiated once-every-12-weeks dosing schedule. For budoprutug in primary membranous nephropathy, the 600 mg dose produced 98% B-cell depletion by Week 4, although higher doses may be needed for patients with nephrotic-range proteinuria. $CLYM
AlertsAndNews
$CLYM Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 "Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027"
focafoca99
$CLYM announced early Phase 2 data showing B-cell depletion and PLA2R antibody reduction in pMN patients.
Rayvio_News_Filter
$CLYM 🏥 Climb Bio, Inc. reported initial Phase 2 data showing low-dose budoprutug (200 mg) achieved B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks in primary membranous nephropathy, with both 200 mg and 600 mg doses generally well tolerated. Market-relevant event
focafoca99
$CLYM released new Phase 1 data showing durable APRIL suppression with 12-week dosing for its CLYM116 candidate.
Rayvio_News_Filter
$CLYM 🏥 Climb Bio, Inc. and Beijing Mabworks Biotech Co., Ltd. presented additional Phase 1 data for CLYM116/MIL116 in healthy volunteers at ASN Kidney Week 2026, showing >90% free APRIL suppression sustained through 12 weeks and ~70% reduction in Gd-IgA1 at 12 weeks. Prioritized by relevance

Advertisement|Remove ads.